{"id":754916,"date":"2023-05-04T09:43:33","date_gmt":"2023-05-04T13:43:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/"},"modified":"2023-05-04T09:43:33","modified_gmt":"2023-05-04T13:43:33","slug":"bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/","title":{"rendered":"BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, May  04, 2023  (GLOBE NEWSWIRE) &#8212; BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023 and provide business highlights.<\/p>\n<p>\n        <strong>Conference Call and Webcast Information<\/strong><br \/>\n        <br \/>Date: May 11, 2023<br \/>Time: 4:30 p.m. ET<br \/>Webcast Link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lMSgzbHfbB30885Z_KB3WKdGaUGeiF-aDYSiJmBVjKZ_P6ngKLmIjBVZZfGcsnU4EHIhAS_RMoRnwHxeigZHN0l2W2NZEfwF9a2cDNPGRi14umHNaevXVr5NB7EDogdjjOngxasFZ9wQcXdJoBuY1dxdayjGKlGeuTjfrlsocErsTqvteMo5aSFE7Ys_We5G\" rel=\"nofollow noopener\" target=\"_blank\">BioAtla First Quarter 2023 Earnings Conference Call<\/a><br \/>Dial-in Numbers: (877) 425-9470 (domestic), (201) 389-0878 (international)<br \/>Conference ID: 13737960<\/p>\n<p>The press release with the financial results will be accessible prior to the conference call through \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SvE8ErKg7CEV1a4jqs4GKLfKKotzO34-0bWp5IWqYY1WWU3Yl9cQJp0V2b6ls1PKj1oY4OBZuEieQHK6pS-ffjcLwWw-G-OzPgIfQBMxmGcW-JDpJhJjlJJbwVwolK4A\" rel=\"nofollow noopener\" target=\"_blank\">News Releases<\/a>\u201d in the News &amp; Events section of the company\u2019s website. A replay of the call will also be available through \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5UbcHUvrWe78Fg5bE0m5PmhrkEWZ62JvJr2z15KZ9_Ow_wxIuLjqC0NPZX3Vk31uFPq3QQjczlgiwpya1wCvJkq1cBDKPvs1y6IdTR2e-gA=\" rel=\"nofollow noopener\" target=\"_blank\">Events &amp; Presentations<\/a>\u201d in the Investors section of the company\u2019s website.<\/p>\n<p>\n        <strong>About BioAtla, Inc.<\/strong><br \/>\n        <br \/>BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with 716 patents (440 issued, 7 allowed, and 269 pending). Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 1 stage CAB-CTLA-4 antibody, BA3071, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company\u2019s first bispecific antibody, BA3182, targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9hk2SQw_XfXljY1GTMrqHXllPCdN0RTSqDjBCrsjILwcO2g67wNysM1h1sEoGr-u3HBKWB4smbXLqjzAD-ld7A==\" rel=\"nofollow noopener\" target=\"_blank\">www.bioatla.com<\/a>.<\/p>\n<p>\n        <strong>Internal Contact:<\/strong><br \/>\n        <br \/>Richard Waldron<br \/>Chief Financial Officer<br \/>BioAtla, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B2krM7SAz-clFO7G7t7x1PAiFtpSzHDP9AjCBBrN3MrOAl5pNVN84pOWHdV_a8-TXKgYQ3av1G4A5hdENWE3SIMCm2oeNDRJwimYpnfm23U=\" rel=\"nofollow noopener\" target=\"_blank\">rwaldron@bioatla.com<\/a><br \/>858.356.8945<\/p>\n<p>\n        <strong>External Contact:<\/strong><br \/>\n        <br \/>Bruce Mackle<br \/>LifeSci Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EQsone9JAOUtC0AXAAzcLBq8BiY9icN2qC-TAJSlVUfu40HByEePSwElitITpx3UhhgrEFd44qZitndY_hJKd0F34FVIOTsOxUduep4dgXaGqLnoj9fmVkJgQDoaGchj\" rel=\"nofollow noopener\" target=\"_blank\">bmackle@lifesciadvisors.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQxNSM1NTczNjU2IzIxOTAxMzU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzNhYWZiMmYtOTNmNC00Y2Q0LWJiOGYtZTg4NGU1MGRlOWMzLTEyMDE2ODg=\/tiny\/BioAtla-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) &#8212; BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023 and provide business highlights. Conference Call and Webcast Information Date: May 11, 2023Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2023 Earnings Conference CallDial-in Numbers: (877) 425-9470 (domestic), (201) 389-0878 (international)Conference ID: 13737960 The press release with the financial results will be accessible prior to the conference call through \u201cNews Releases\u201d in the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754916","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) &#8212; BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023 and provide business highlights. Conference Call and Webcast Information Date: May 11, 2023Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2023 Earnings Conference CallDial-in Numbers: (877) 425-9470 (domestic), (201) 389-0878 (international)Conference ID: 13737960 The press release with the financial results will be accessible prior to the conference call through \u201cNews Releases\u201d in the &hellip; Continue reading &quot;BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T13:43:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQxNSM1NTczNjU2IzIxOTAxMzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023\",\"datePublished\":\"2023-05-04T13:43:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\\\/\"},\"wordCount\":403,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQxNSM1NTczNjU2IzIxOTAxMzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\\\/\",\"name\":\"BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQxNSM1NTczNjU2IzIxOTAxMzU=\",\"datePublished\":\"2023-05-04T13:43:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQxNSM1NTczNjU2IzIxOTAxMzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQxNSM1NTczNjU2IzIxOTAxMzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/","og_locale":"en_US","og_type":"article","og_title":"BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023 - Market Newsdesk","og_description":"SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) &#8212; BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023 and provide business highlights. Conference Call and Webcast Information Date: May 11, 2023Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2023 Earnings Conference CallDial-in Numbers: (877) 425-9470 (domestic), (201) 389-0878 (international)Conference ID: 13737960 The press release with the financial results will be accessible prior to the conference call through \u201cNews Releases\u201d in the &hellip; Continue reading \"BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-04T13:43:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQxNSM1NTczNjU2IzIxOTAxMzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023","datePublished":"2023-05-04T13:43:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/"},"wordCount":403,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQxNSM1NTczNjU2IzIxOTAxMzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/","name":"BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQxNSM1NTczNjU2IzIxOTAxMzU=","datePublished":"2023-05-04T13:43:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQxNSM1NTczNjU2IzIxOTAxMzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQxNSM1NTczNjU2IzIxOTAxMzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-first-quarter-2023-financial-results-and-provide-business-highlights-on-may-11-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754916"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754916\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}